![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New York, NY -- October 6, 2020 -- InvestorsHub NewsWire -- via The Motley Fool -- Special Purpose Acquisition Companies (SPACs) set the overall electric vehicle (EV) market on fire in August and...
August 31, 2020 -- InvestorsHub NewsWire -- via Borneo Post -- Corporate Malaysia has certainly seen an upset in the form of the Covid-19 pandemic, leading some firms to reevaluate...
Submitted proposal to BARDA for start-to-finish funding to develop an approved, commercial Ii-Key peptide vaccine against the SARS-CoV-2 coronavirus SARS-CoV-2 epitope identification and...
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclusion: AE37 Ii-Key...
Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development Generex strategy offers...
GNBT - Generex Biotechnology Signs Stock Purchase Agreement to Acquire 51% of ALTuCELL, Inc. Closing Scheduled for December 2019 Patented AltuCapsÒ for Microencapsulation of stem...
Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells) Principal investigator Dr...
GNBT – BioPharma w/10x Potential – Cancer and Diabetes Treatments – Nasdaq Up List Under $2 PPS With Potential To Over $10 In Near Term Phase III Trials On Horizon For...
WHY GNBT COULD MOVE BIG SOON October 23, 2019 -- InvestorsHub NewsWire -- via Seeking Alpha Oct. 23, 2019 10:05 AM ET|About: Generex Biotechnology Corp...
MIRAMAR, FL -- October 01, 2019 -- InvestorsHub NewsWire -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is pleased...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions